Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma.

Gossai N, Cafferty R, Weigel B.

Curr Treat Options Oncol. 2016 Jul;17(7):38. doi: 10.1007/s11864-016-0411-7. Review.

PMID:
27300546
2.

Inhibitors of histone deacetylase as antitumor agents: A critical review.

Manal M, Chandrasekar MJ, Gomathi Priya J, Nanjan MJ.

Bioorg Chem. 2016 Aug;67:18-42. doi: 10.1016/j.bioorg.2016.05.005. Epub 2016 May 17. Review.

PMID:
27239721
3.

Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.

Damaskos C, Garmpis N, Karatzas T, Nikolidakis L, Kostakis ID, Garmpi A, Karamaroudis S, Boutsikos G, Damaskou Z, Kostakis A, Kouraklis G.

Anticancer Res. 2015 Jun;35(6):3129-35. Review.

PMID:
26026072
4.

Epigenetic drugs against cancer: an evolving landscape.

Di Costanzo A, Del Gaudio N, Migliaccio A, Altucci L.

Arch Toxicol. 2014 Sep;88(9):1651-68. doi: 10.1007/s00204-014-1315-6. Epub 2014 Aug 2. Review.

PMID:
25085708
5.

Systematic review of combination therapies for mycosis fungoides.

Humme D, Nast A, Erdmann R, Vandersee S, Beyer M.

Cancer Treat Rev. 2014 Sep;40(8):927-33. doi: 10.1016/j.ctrv.2014.06.005. Epub 2014 Jun 19. Review.

PMID:
24997678
6.

Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.

Nakamura R, Forman SJ.

Expert Rev Hematol. 2014 Jun;7(3):407-21. doi: 10.1586/17474086.2014.898561. Epub 2014 Apr 4. Review.

PMID:
24702163
7.

Advances in paediatric cancer treatment.

Saletta F, Seng MS, Lau LM.

Transl Pediatr. 2014 Apr;3(2):156-82. doi: 10.3978/j.issn.2224-4336.2014.02.01. Review.

8.

Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.

McNeil C.

J Natl Cancer Inst. 2013 Jul 3;105(13):922-3. doi: 10.1093/jnci/djt179. Epub 2013 Jun 18. No abstract available.

PMID:
23781000
9.

Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?

Koutsounas I, Giaginis C, Theocharis S.

World J Gastroenterol. 2013 Feb 28;19(8):1173-81. doi: 10.3748/wjg.v19.i8.1173. Review.

10.

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.

Ververis K, Hiong A, Karagiannis TC, Licciardi PV.

Biologics. 2013;7:47-60. doi: 10.2147/BTT.S29965. Epub 2013 Feb 25.

11.

Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.

Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ.

Thyroid. 2013 Apr;23(4):392-407. doi: 10.1089/thy.2012.0520. Review.

PMID:
23294230
12.

Influence of natural and synthetic histone deacetylase inhibitors on chromatin.

Licciardi PV, Kwa FA, Ververis K, Di Costanzo N, Balcerczyk A, Tang ML, El-Osta A, Karagiannis TC.

Antioxid Redox Signal. 2012 Jul 15;17(2):340-54. doi: 10.1089/ars.2011.4480. Epub 2012 Feb 9. Review.

PMID:
22229817
13.

Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells.

Zhou Q, Chaerkady R, Shaw PG, Kensler TW, Pandey A, Davidson NE.

Proteomics. 2010 Mar;10(5):1029-39. doi: 10.1002/pmic.200900602.

14.

Molecular targets in malignant pleural mesothelioma treatment.

Pasello G, Favaretto A.

Curr Drug Targets. 2009 Dec;10(12):1235-44. Review.

PMID:
19909234

Supplemental Content

Loading ...
Support Center